-
Je něco špatně v tomto záznamu ?
Survival associated with the use of sentinel lymph node in addition to lymphadenectomy in early-stage cervical cancer treated with surgery alone: A sub-analysis of the Surveillance in Cervical CANcer (SCCAN) collaborative study
N. Bizzarri, D. Querleu, PT. Ramirez, L. Dostálek, LRW. van Lonkhuijzen, D. Giannarelli, A. Lopez, S. Salehi, A. Ayhan, SH. Kim, D. Isla Ortiz, J. Klat, F. Landoni, R. Pareja, R. Manchanda, J. Kosťun, MM. Meydanli, D. Odetto, R. Laky, I....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, multicentrická studie
- MeSH
- biopsie sentinelové lymfatické uzliny metody MeSH
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- lymfadenektomie * metody MeSH
- lymfatické metastázy MeSH
- nádory děložního čípku * patologie chirurgie mortalita MeSH
- retrospektivní studie MeSH
- senioři MeSH
- sentinelová uzlina * patologie chirurgie MeSH
- spinocelulární karcinom chirurgie patologie mortalita MeSH
- staging nádorů MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
AIM: The aim of this study was to assess whether the use of sentinel lymph node (SLN) in addition to lymphadenectomy was associated with survival benefit in patients with early-stage cervical cancer. METHODS: International, multicenter, retrospective study. INCLUSION CRITERIA: cervical cancer treated between 01/2007 and 12/2016 by surgery only; squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, FIGO 2009 stage IB1-IIA2, negative surgical margins, and laparotomy approach. Patients undergoing neo-adjuvant and/or adjuvant treatment and/or with positive para-aortic lymph nodes, were excluded. Women with positive pelvic nodes who refused adjuvant treatment, were included. Lymph node assessment was performed by SLN (with ultrastaging protocol) plus pelvic lymphadenectomy ('SLN' group) or pelvic lymphadenectomy alone ('non-SLN' group). RESULTS: 1083 patients were included: 300 (27.7 %) in SLN and 783 (72.3 %) in non-SLN group. 77 (7.1 %) patients had recurrence (N = 11, 3.7 % SLN versus N = 66, 8.4 % non-SLN, p = 0.005) and 34 (3.1 %) (N = 4, 1.3 % SLN versus N = 30, 3.8 % non-SLN, p = 0.033) died. SLN group had better 5-year disease-free survival (DFS) (96.0 %,95 %CI:93.5-98.5 versus 92.0 %,95 %CI:90.0-94.0; p = 0.024). No 5-year overall survival (OS) difference was shown (98.4 %,95 %CI:96.8-99.9 versus 96.8 %,95 %CI:95.4-98.2; p = 0.160). SLN biopsy and lower stage were independent factors associated with improved DFS (HR:0.505,95 %CI:0.266-0.959, p = 0.037 and HR:2.703,95 %CI:1.389-5.261, p = 0.003, respectively). Incidence of pelvic central recurrences was higher in the non-SLN group (1.7 % versus 4.5 %, p = 0.039). CONCLUSION: Adding SLN biopsy to pelvic lymphadenectomy was associated with lower recurrence and death rate and improved 5-year DFS. This might be explained by the lower rate of missed nodal metastasis thanks to the use of SLN ultrastaging. SLN biopsy should be recommended in patients with early-stage cervical cancer.
Department of Gynaecological Oncology Barts Health NHS Trust London UK
Department of Gynecologic Oncology Barretos Cancer Hospital Barretos Sao Paulo Brazil
Department of Gynecologic Oncology Instituto Nacional de Cancerología Bogotá Colombia
Department of Gynecological Surgery National Institute of Neoplastic Diseases Lima Peru
Department of Obstetrics and Gynecology Houston Methodist Hospital Houston TX USA
Gynecologic Oncology Unit La Paz University Hospital Madrid Spain
Gynecology Medical University of Graz Graz Austria
Gynecology Oncology Center National Institute of Cancerology Mexico Mexico City Mexico
IRCCS Fondazione San Gerardo Università Milano Bicocca Monza Italy
Memorial Sloan Kettering Cancer Center New York USA
Oncology Unit of the Cayetano Heredia Hospital Lima Peru
University Hospital Brno Medical Faculty of Masaryk University Brno Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24018664
- 003
- CZ-PrNML
- 005
- 20241024111303.0
- 007
- ta
- 008
- 241015e20240912enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejca.2024.114310 $2 doi
- 035 __
- $a (PubMed)39270379
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Bizzarri, Nicolò $u UOC Ginecologia Oncologica, Dipartimento di Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy. Electronic address: nicolo.bizzarri@yahoo.com
- 245 10
- $a Survival associated with the use of sentinel lymph node in addition to lymphadenectomy in early-stage cervical cancer treated with surgery alone: A sub-analysis of the Surveillance in Cervical CANcer (SCCAN) collaborative study / $c N. Bizzarri, D. Querleu, PT. Ramirez, L. Dostálek, LRW. van Lonkhuijzen, D. Giannarelli, A. Lopez, S. Salehi, A. Ayhan, SH. Kim, D. Isla Ortiz, J. Klat, F. Landoni, R. Pareja, R. Manchanda, J. Kosťun, MM. Meydanli, D. Odetto, R. Laky, I. Zapardiel, V. Weinberger, R. Dos Reis, L. Pedone Anchora, K. Amaro, H. Akilli, NR. Abu-Rustum, RA. Salcedo-Hernández, V. Javůrková, CH. Mom, H. Falconer, G. Scambia, D. Cibula
- 520 9_
- $a AIM: The aim of this study was to assess whether the use of sentinel lymph node (SLN) in addition to lymphadenectomy was associated with survival benefit in patients with early-stage cervical cancer. METHODS: International, multicenter, retrospective study. INCLUSION CRITERIA: cervical cancer treated between 01/2007 and 12/2016 by surgery only; squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, FIGO 2009 stage IB1-IIA2, negative surgical margins, and laparotomy approach. Patients undergoing neo-adjuvant and/or adjuvant treatment and/or with positive para-aortic lymph nodes, were excluded. Women with positive pelvic nodes who refused adjuvant treatment, were included. Lymph node assessment was performed by SLN (with ultrastaging protocol) plus pelvic lymphadenectomy ('SLN' group) or pelvic lymphadenectomy alone ('non-SLN' group). RESULTS: 1083 patients were included: 300 (27.7 %) in SLN and 783 (72.3 %) in non-SLN group. 77 (7.1 %) patients had recurrence (N = 11, 3.7 % SLN versus N = 66, 8.4 % non-SLN, p = 0.005) and 34 (3.1 %) (N = 4, 1.3 % SLN versus N = 30, 3.8 % non-SLN, p = 0.033) died. SLN group had better 5-year disease-free survival (DFS) (96.0 %,95 %CI:93.5-98.5 versus 92.0 %,95 %CI:90.0-94.0; p = 0.024). No 5-year overall survival (OS) difference was shown (98.4 %,95 %CI:96.8-99.9 versus 96.8 %,95 %CI:95.4-98.2; p = 0.160). SLN biopsy and lower stage were independent factors associated with improved DFS (HR:0.505,95 %CI:0.266-0.959, p = 0.037 and HR:2.703,95 %CI:1.389-5.261, p = 0.003, respectively). Incidence of pelvic central recurrences was higher in the non-SLN group (1.7 % versus 4.5 %, p = 0.039). CONCLUSION: Adding SLN biopsy to pelvic lymphadenectomy was associated with lower recurrence and death rate and improved 5-year DFS. This might be explained by the lower rate of missed nodal metastasis thanks to the use of SLN ultrastaging. SLN biopsy should be recommended in patients with early-stage cervical cancer.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a nádory děložního čípku $x patologie $x chirurgie $x mortalita $7 D002583
- 650 12
- $a lymfadenektomie $x metody $7 D008197
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 12
- $a sentinelová uzlina $x patologie $x chirurgie $7 D000071036
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a biopsie sentinelové lymfatické uzliny $x metody $7 D021701
- 650 _2
- $a lymfatické metastázy $7 D008207
- 650 _2
- $a spinocelulární karcinom $x chirurgie $x patologie $x mortalita $7 D002294
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Querleu, Denis $u UOC Ginecologia Oncologica, Dipartimento di Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy
- 700 1_
- $a Ramirez, Pedro T $u Department of Obstetrics and Gynecology, Houston Methodist Hospital, Houston, TX, USA
- 700 1_
- $a Dostálek, Lukáš $u Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital (Central and Eastern European Gynecologic Oncology Group, CEEGOG), Prague, Czech Republic
- 700 1_
- $a van Lonkhuijzen, Luc Rc W $u Center for Gynaecologic Oncology Amsterdam, Amsterdam University Medical Centers, Amsterdam, the Netherlands
- 700 1_
- $a Giannarelli, Diana $u Biostatistics Unit, Scientific Directorate, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy
- 700 1_
- $a Lopez, Aldo $u Department of Gynecological Surgery, National Institute of Neoplastic Diseases, Lima, Peru
- 700 1_
- $a Salehi, Sahar $u Department of Pelvic Cancer, Karolinska University Hospital and Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden
- 700 1_
- $a Ayhan, Ali $u Baskent University School of Medicine, Department of Gynecology and Obstetrics, Division of Gynecologic Oncology, Ankara, Turkey
- 700 1_
- $a Kim, Sarah H $u Memorial Sloan Kettering Cancer Center, New York, USA
- 700 1_
- $a Isla Ortiz, David $u Gynecology Oncology Center, National Institute of Cancerology Mexico, Mexico City, Mexico
- 700 1_
- $a Klat, Jaroslav $u Department of Obstetrics and Gynecology, Faculty of Medicine, University Hospital and University of Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Landoni, Fabio $u IRCCS Fondazione San Gerardo - Università Milano Bicocca, Monza, Italy
- 700 1_
- $a Pareja, Rene $u Department of Gynecologic Oncology, Instituto Nacional de Cancerología, Bogotá, Colombia
- 700 1_
- $a Manchanda, Ranjit $u Wolfson Institute of Population Health, Barts Cancer Centre, Queen Mary University of London, & Barts Health NHS Trust, London, UK; Department of Gynaecological Oncology, Barts Health NHS Trust, London, UK; Department of Health Services Research | Faculty of Public Health & Policy | London School of Hygiene & Tropical Medicine, London, UK
- 700 1_
- $a Kosťun, Jan $u Department of Gynaecology and Obstetrics, University Hospital Pilsen, Charles University, Prague, Czech Republic
- 700 1_
- $a Meydanli, Mehmet M $u Department of Gynecologic Oncology, Zekai Tahir Burak Women's Health and Research Hospital, University of Health Sciences, Ankara, Turkey
- 700 1_
- $a Odetto, Diego $u Department of Gynecologic Oncology, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano, Buenos Aires, Argentina
- 700 1_
- $a Laky, Rene $u Gynecology, Medical University of Graz, Graz, Austria
- 700 1_
- $a Zapardiel, Ignacio $u Gynecologic Oncology Unit, La Paz University Hospital, Madrid, Spain
- 700 1_
- $a Weinberger, Vit $u University Hospital Brno, Medical Faculty of Masaryk University, Brno, Czech Republic
- 700 1_
- $a Dos Reis, Ricardo $u Department of Gynecologic Oncology, Barretos Cancer Hospital, Barretos, Sao Paulo, Brazil
- 700 1_
- $a Pedone Anchora, Luigi $u UOC Ginecologia Oncologica, Dipartimento di Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy
- 700 1_
- $a Amaro, Karina $u Oncology Unit of the Cayetano Heredia Hospital, Lima, Peru
- 700 1_
- $a Akilli, Huseyin $u Baskent University School of Medicine, Department of Gynecology and Obstetrics, Division of Gynecologic Oncology, Ankara, Turkey
- 700 1_
- $a Abu-Rustum, Nadeem R $u Memorial Sloan Kettering Cancer Center, New York, USA
- 700 1_
- $a Salcedo-Hernández, Rosa A $u Gynecology Oncology Center, National Institute of Cancerology Mexico, Mexico City, Mexico
- 700 1_
- $a Javůrková, Veronika $u Department of Obstetrics and Gynecology, Faculty of Medicine, University Hospital and University of Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Mom, Constantijne H $u Center for Gynaecologic Oncology Amsterdam, Amsterdam University Medical Centers, Amsterdam, the Netherlands
- 700 1_
- $a Falconer, Henrik $u Department of Pelvic Cancer, Karolinska University Hospital and Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden
- 700 1_
- $a Scambia, Giovanni $u UOC Ginecologia Oncologica, Dipartimento di Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy
- 700 1_
- $a Cibula, David $u Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital (Central and Eastern European Gynecologic Oncology Group, CEEGOG), Prague, Czech Republic
- 773 0_
- $w MED00009626 $t European journal of cancer (Oxford, England : 1990) $x 1879-0852 $g Roč. 211 (20240912), s. 114310
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39270379 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241015 $b ABA008
- 991 __
- $a 20241024111257 $b ABA008
- 999 __
- $a ok $b bmc $g 2201512 $s 1230637
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 211 $c - $d 114310 $e 20240912 $i 1879-0852 $m European journal of cancer (Oxford, England : 1990) $n Eur J Cancer $x MED00009626
- LZP __
- $a Pubmed-20241015
